Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,003 public trials 2,033 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, not recruiting

Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL

NCT03962465

Conditions
B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +15 more
Locations
  • Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States
  • University of Virginia Charlottesville, Virginia, United States
  • VCU Massey Cancer Center Richmond, Virginia, United States
  • University of Wisconsin Madison, Wisconsin, United States
View Trial Details
Active, not recruiting

Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

NCT03948035

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Univ. Klinikum Krems Krems, Lower Austria, Austria
  • Universitätklinikum St. Pölten Sankt Pölten, Lower Austria, Austria
  • LKH-Universitätsklinikum Graz Graz, Styria, Austria
  • Medizinische Universität Innsbruck Innsbruck, Tyrol, Austria
View all 56 locations
View Trial Details
Active, not recruiting

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

NCT04526834

Conditions
Anaplastic Large Cell Lymphoma, Diffuse Large B Cell Lymphoma, Extranodal NK/T-cell Lymphoma, +17 more
Locations
  • City of Hope Duarte, California, United States
  • Sarah Cannon Research Institute Nashville, Tennessee, United States
  • Baylor College of Medicine Houston, Texas, United States
  • The University of Texas MD Anderson Cancer Centre Houston, Texas, United States
View Trial Details
Active, not recruiting

Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

NCT04268706

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Disease Recurrent, +10 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of Chicago Medical Center Chicago, Illinois, United States
  • Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States
  • Sarah Cannon Research Institute Nashville, Tennessee, United States
View Trial Details
Active, not recruiting

Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma

NCT02544308

Conditions
Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, +4 more
Locations
  • Royal United Hospital Bath, United Kingdom
  • Blackpool Victoria Hospital Blackpool, United Kingdom
  • University Hospital Wales Cardiff, United Kingdom
  • Velindre Cancer Centre Cardiff, United Kingdom
View all 13 locations
View Trial Details
Active, not recruiting

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

NCT02415413

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations
  • Hospital Clínic de Barcelona Barcelona, Spain
  • Hospital Universitari Germans Trias i Pujol Barcelona, Spain
  • Hospital Clínico San Carlos Madrid, Spain
  • Hospital Universitario 12 de Octubre Madrid, Spain
View all 16 locations
View Trial Details

Related conditions